Wijk et al. [15] reported an interaction between Gal-3 and β-blocker efficacy, with low Gal-3 patients deriving greater survival benefits from up-titration (HR: 2.42 in TIME-CHF, p = 0.02). The gene discussed is LGALS3; the disease is congestive heart failure.